Citations 1497

IC‐01‐01: Predictors of Regional TAU‐PET Uptake: Mayo Clinic Study of Aging

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.061

P1‐262: Comparison of [18F]Flutametamol and [11C]PIB in Normal Young, Normal Elderly, and Alzheimer's Disease Subjects

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.1011

P1‐261: Association of [18F]AV‐1451 TAU Markers with Cognitive and Neurodegeneration Measures: Preliminary Analysis in The Adni Cohort

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.1010

O1‐07‐01: A Longitudinal Morphometric Study of Familial Alzheimer’s Disease: Results From DIAN

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.329

IC‐01‐05: Neuropathologic Features of AV1451 TAU Pet Autoradiography in Dementia

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.065

O2‐03‐02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN)

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.406

Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity

Journal of Alzheimer's Disease | October 14, 2016 | Volume: 55 | Issue: 3 | Pages: 1019-1029

10.3233/jad-160614 | PMID 27802232

Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status

The Clinical Neuropsychologist | October 11, 2016 | Volume: 31 | Issue: 1 | Pages: 99-117

10.1080/13854046.2016.1241303 | PMID 27724156

Defining imaging biomarker cut points for brain aging and Alzheimer's disease

Alzheimer's & Dementia | October 5, 2016 | Volume: 13 | Issue: 3 | Pages: 205-216

10.1016/j.jalz.2016.08.005 | PMID 27697430

Abstract Introduction Our goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro‐deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We examined five methods for determining cut points. Results The reliable worsening method produced a cut point only for amyloid PET. The specificity, sensitivity, and accuracy of cognitively impaired versus young clinically normal (CN) methods labeled the most people abnormal and all gave similar cut points for tau PET, FDG PET, and cortical thickness. Cut points defined using the accuracy of cognitively impaired versus age‐matched CN method labeled fewer people abnormal. Discussion In the future, we will use a single cut point for amyloid PET (standardized uptake value ratio, 1.42; centiloid, 19) based on the reliable worsening cut point method. We will base lenient cut points for tau PET, FDG PET, and cortical thickness on the accuracy of cognitively impaired versus young CN method and base conservative cut points on the accuracy of cognitively impaired versus age‐matched CN method.
Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging

The Journal of Neuropsychiatry and Clinical Neurosciences | August 31, 2016 | Volume: 29 | Issue: 1 | Pages: 60-66

10.1176/appi.neuropsych.15100378 | PMID 27578447